This applies particularly to idiopathic pulmonary fibrosis, for which the ATX inhibitor GLPG1690 (ziritaxestast) and LPAR1 receptor antagonist BMS-986020 have entered clinical trials [20,21]. This evidence concerns the gene ENPP2 and pulmonary fibrosis.